Session 1.1: Age-related Macular Degeneration: A Focus on Durability
Presentation by Arshad Khanani, MD
Updated Results of Phase 1b Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate w Durability, in wAMD, DME, and RVO
*Data presentation same as July 10 data
Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.